rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Outcomes of Smoker and Drinker With Esophageal Squamous Cell Carcinoma After Esophagectomy
Status: Recruiting

Our study demonstrates that patients who did not consume alcohol or smoke had a significant advantage in overall survival (OS) after undergoing esophagectomy. Furthermore, our findings indicate that there was no statistically significant difference in OS between patients with a history of both smoking and drinking, and those who only smoked or drank

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  patients with esophageal cancer  Exclusion Criteria:  (1) pathology confirmed a non-squamous cell carcinoma, (2) the tumor was located outside of the thoracic region, (3) R1/R2 resection was performed indicating incomplete tumor removal, (4) evidence of distant tumor metastasis was observed, (5) they underwent preoperative neoadjuvant therapy, (6) pTis/T1a stage (7) Missing data. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 90 Years - StdAgeList: Adult, Older Adult - StudyPopulation: patients with esophageal cancer - SamplingMethod: Non-Probability Sample
Assessment of Skin Barrier Disruption Due to Daily Use of Cleaning Products and Hand Disinfectants
Status: Not yet recruiting

The goal of this clinical trial is to assess the effects of household detergents and hand disinfectants on human skin barrier integrity among healthy adult volunteers.

The main questions it aims to answer are:

How does exposure to household detergents and hand disinfectants impact skin barrier function?
Are there differences in skin barrier disruption between various types of cleaning agents and disinfectants?

Participants will:

Undergo patch testing with controlled amounts of household detergents and hand disinfectants on a small area of their skin.

Be monitored for adverse reactions during and after exposure. Have their skin barrier integrity assessed using electrical impedance spectroscopy at multiple time points post-exposure.

If there is a comparison group:

Researchers will compare the effects of different types of cleaning agents, hand disinfectants, and their ingredients on skin barrier integrity to determine variations in their impact.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  The study population will consist of healthy adult volunteers; 1. age between18 and 65 years, 2. Generally healthy and able to provide written informed consent. The choice of healthy adult volunteers without pre-existing skin conditions on site or allergies against tested products is justified.  Exclusion Criteria:  Severe dermatitis, eczema, psoriasis, or other chronic skin conditions. History of hypersensitivity or allergies to tested product ingredients. Current or recent systemic therapy for a skin condition in the past six months. Pregnant or breastfeeding individuals. Use of investigational drugs or participation in another trial in the last 30 days. History of skin cancer or malignancies in the study area. Significant sunburn, open wounds, or active skin infections in the study area. Any medical condition that, per the investigator, might compromise safety or confound results. Inability to follow study instructions or attend required clinic visits. Gender Balance: To ensure gender balance, efforts will be made to recruit an equal number of male and female participants. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
Effects of Web-Based Education on Patient Empowerment and Asthma Control in Asthma Patients
Status: Not yet recruiting

Asthma is defined as a chronic inflammatory disorder of the airways associated with an extreme increase in airway hyperresponsiveness leading to recurrent wheezing, shortness of breath, chest tightness, and coughing attacks. The World Health Organization states that approximately 339 million individuals worldwide have asthma and more than 400 thousand deaths occur due to asthma every year.

With effective and sustainable asthma management, it is possible to reduce disease-related complaints, admissions to emergency units and hospitalizations, limit the physiological and psychological effects of the disease, prevent dependence on healthcare professionals and caregivers, increase the quality of life and reduce the mortality of the disease. Patient education, which is within the educational role of professional nurses, is very important in asthma management. The research was planned in a single-center, randomized control group pretest-posttest design. The sample will consist of individuals who applied to the Allergy and Immunology clinic of Sureyyapasa Chest Diseases and Surgery Training and Research Hospital between May 2024 and January 2024, who have been diagnosed with asthma for at least one year and who accept the study [25 intervention group - 25 control group]. Groups will be determined using the random numbers table from the simple random sampling method. A web-based asthma education module will be created in line with the literature, and participants in the intervention group will be given synchronous training in 5 modules. After meeting the individuals in the intervention and control groups and obtaining verbal and written consent, they will be asked to fill out the Patient Information Form, Patient Empowerment Scale and Asthma Control Test prepared via Google Forms. A 30-minute training session will be given to the intervention group every week and there will be short evaluations after each training. When the 5th Module is completed, the intervention group will be asked to fill out the Patient Empowerment Scale and Asthma Control Test Scale. No intervention will be applied to the control group. 5. At the end of the module, the Patient Empowerment Scale and Asthma Control Test will be completed by individuals in the control group. It is thought that web-based asthma education that individuals will receive will positively affect their empowerment levels and increase their disease control.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Receiving treatment with a diagnosis of asthma for at least 1 year Having severe asthma Not having had any previous training Being between the ages of 18-65, Knowing how to read, write, Volunteering to participate in research  Exclusion Criteria:  Having received treatment for less than 1 year Being educated, Not being at the level of severe asthma, Not meeting the age criterion, Not having the ability to understand, read and write Turkish - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
Pilot Study to Determine Feasibility of Home-based Cardiac Rehabilitation in Patients With Chronic Heart Failure (Pilot-CRHF)
Status: Not yet recruiting

The proposed study will determine the willingness of patients for participation. Furthermore, the assessment of tests to identify eligible patients and the type of exercise intervention that goes along with a high patient compliance is crucial. Also, more information about possible factors preventing patients from participating is required. Therefore, if the patient is willing to participate, we will assess patients' medical history, medication and QoL as well as parameters of routine diagnostics (i.e. echocardiography, laboratory testing, MRI). Following, while the in-patient stay due to cardiac decompensation, we will conduct several assessment-tests to determine the physical status, the exercise capacity and the cognitive function. Moreover, physiotherapists will instruct the patients in the exercise program. After discharge from the hospital, physiotherapist will visit the patient at home to instruct them again in the exercises. Then, the patients will conduct the program on their own for a period of 12 weeks. During the exercise period, a doctoral student will visit the patients at home every 3 weeks to check whether they are doing the exercises correctly and to determine whether there are any problems with the program. After the exercise period of 12 weeks, the baseline characteristics will be assessed again at the University Hospital Leipzig.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  1. Chronic heart failure irrespective of the ejection fraction 2. After acute cardiac decompensation leading to hospitalization  Exclusion Criteria:  1. Patients not willing to participate 2. Patients with orthopedic diseases limiting their mobility 3. Cognitive diseases that hinder adequate participation in the opinion of the investigator 4. Inpatient rehabilitation. - HealthyVolunteers: No - Gender: All - StdAgeList: Child, Adult, Older Adult
Acceptance and Perceived Benefits of Digitalization by Medical Assistants
Status: Recruiting

The aim of this project is to improve the integration of digital processes, including e-prescriptions, within medical and dental practices for healthcare professionals. Through a better understanding of the obstacles healthcare workers encounter during the adoption of digital processes and their feedback post-implementation, this study will add to the current state of science, contributing to digital process optimization in healthcare.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  - Ability to participate in surveys (e.g., sufficient German or English language skills)  Exclusion Criteria:  Younger than 18 years Illiteracy Massively limited cognitive abilities, i.e., linguistic components of the digital offerings must be able to be used to complete questionnaires or participate in interviews - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Health Care Workers, including medical assistances - SamplingMethod: Non-Probability Sample
Point of Care Test of LTA Level in Tear Fluid, Measured With a POCT Test, in DE Patients Following IPL Treatment
Status: Not yet recruiting

To quantify and compare tear levels of Intense pulsed light (IPL) and traditional dry eye clinical tests in dry eye patients before and after Intense pulsed light (IPL) treatment.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  age ≥ 18 years Fitzpatrick skin types I to IV capable and willing to comply with the treatment and follow-up obligations a determination of DED based on (a) the Ocular Surface Disease Index (OSDI) ≥13 score represents severe DED, (b) non-invasive tear film breakup time (NITBUT) of ≤5 sec, or conjunctivocorneal staining score (CS) ≥3 points according to the Japanese Dry Eye Consensus  Exclusion Criteria:  Existing ocular trauma, infectious diseases, recent surgical history Skin defects, pigmentation, moles, scars in the treatment area, skin cancer Autoimmune diseases, skin allergies. Pregnancy or lactation Fitzpatrick skin type V or VI. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 90 Years - StdAgeList: Adult, Older Adult
Postoperative Complications in Cancer Patients Monitored With Intelligent Continuous Monitoring System
Status: Recruiting

The primary objective of this study is to determine the effect on complication severity of using a clinical monitoring system with automatic vital sign alerts in addition to routine monitoring versus routine monitoring alone in high-risk postoperative cancer patients within 30 days after surgery.

Other objectives include documentation of the severity of complications within seven days of surgery, frequency of serious adverse events, mortality, length of stay and delay of planned chemotherapy.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Admission for elective major abdominal (gastrointestinal, gynecological, or urological) surgery with the primary aim of radical surgery/removing suspected cancer tissue. At least two expected postoperative admission days Laparotomy or laparoscopy procedure estimated to last more than 2 hours. Co-enrolment of patients in other studies is acceptable but in studies involving interventions which potentially will affect the continuous monitoring of vital signs and/or the primary or secondary outcomes, an assessment of whether these patients can be co-enrolled in the WARD-RCT should be conferred with the WARD RCT steering committee.  Exclusion Criteria:  Patient expected not to cooperate with study procedures Allergy to study materials (silicone, plaster) Impaired cognitive function (in uncertain cases assessed by a Mini Mental State Examination score < 24). (Protocol Appendix E) Patients with a pacemaker or Implantable Cardioverter Defibrillator (ICD) device Inability to give informed consent Patients with planned hyperthermic intraperitoneal chemotherapy (HIPEC) procedure or two-stage resections (two-stage hepatectomy, two-stage resection of malignant colorectal obstructions, etc.) - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis
Status: Not yet recruiting

Anti-TNF (tumor necrosing factor) treatment with infliximab (IFX) and adalimumab (ADA) are established first-line biological therapies used in treatment of patients with ulcerative colitis (UC). There are no head-to-head comparative studies between these two drug but meta-analysis of randomized controlled trials states that IFX might be more effective than ADA for the induction of clinical remission. However, several observational studies conclude that ADA seem to have similar effect as IFX in treating patients with UC but these studies have limitations.

The overall aim of this retrospective multicenter observational cohort study is to evaluate if there is a difference in efficacy between infliximab (IFX) and adalimumab (ADA) in treating bio-naive patients with UC in the short and long term during the modern era when therapeutic drug monitoring have been used to optimize anti-TNF treatment.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age 18-100 years. Diagnosis of ulcerative colitis confirmed by endoscopy and histology. Mild, moderate and severe disease activity. Initiation of IFX or ADA-treatment at one of the centers of the study.  Exclusion Criteria:  Clinical remission. Previous colonic surgery (resection of colonic segment or colectomy). Primary indication for anti-TNF therapy by other disease than UC. Prior use of any anti-TNF or other biologic or small molecule therapy. Rescue therapy (i.e. infliximab used on hospitalized patients receiving intravenous corticosteroids). - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 100 Years - StdAgeList: Adult, Older Adult - StudyPopulation: We will perform a retrospective multicenter observational cohort study according to the Newcastle-Ottawa Scale (NOS) quality instrument. Bionaive patients (i.e. no prior anti-TNF or other biologic treatment) with active UC, who started treatment with IFX or ADA at four major out-patient IBD-units (Inflammatory Bowel Disease) in the region Västra Götaland in Sweden, will be included in the study. Data regarding exposure for the two compared drugs, baseline characteristics and outcomes after three months and one year will be recieved by a structured review of medical records. - SamplingMethod: Probability Sample
The Power of 24-hour: Co-designing Intervention Components
Status: Recruiting

Most of the existing lifestyle interventions in adults with overweight or obesity focus on one movement behavior in isolation (i.e. moderate to vigorous physical activity (MVPA)). However, recent research suggests to incorporate all movement behaviors performed in one day to explore the possible synergistic health effects of targeting more than one behavior. Moreover, more optimal 24-hour movement behavior compositions are related with better cardiometabolic health. Literature shows that adults with obesity have less optimal 24-hour compositions (8-9). Therefore it would be of interest to discover the needs related to an optimal 24-hour movement behavior intervention for a group of adults with overweight and obesity using co-design to develop an intervention.

This study will conduct a concept mapping protocol to explore the needs to of people with overweight and obesity to change their sedentary behavior into more physical activity as well to include the opinion of health care providers (HCP are physiotherapists) on the needs of their patients.

Eligibility:
- EligibilityCriteria: Group Health Care providers  Inclusion Criteria:  The HCP will consist of physiotherapists and movement on referral coaches (https://www.gezondleven.be/projecten/bewegen-op-verwijzing). HCP are included when working on a healthy lifestyle as well as working with clients struggling with overweight or obesity.  Group Adults with overweight and obesity  Inclusion Criteria:  Adults aged 25-64 years Active on the job market for at least 50 percent BMI ≥25kg/m²  Exclusion Criteria:  - Retirement and early retirement Unemployment Working for less than 50 percent Working in night shifts Physical (e.g. amputations, paralysis, recovering from stroke, osteoarthritis), cognitive (e.g. dementia, psychological disorders) and major medical (e.g. Chronic respiratory diseases, heart failure, cardiovascular diseases, cancer) conditions that obstruct daily functioning Diabetes diagnosed by a general practitioner Pregnancy Pregnancy <1 year ago Currently involved in study specific weight loss interventions Post-surgery weight loss interventions Waitlist for weight loss surgery Hospitalized - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 25 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult - StudyPopulation: A group of health care providers as a group of adults with overweight and obesity will be included. - SamplingMethod: Probability Sample
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
Status: Not yet recruiting

This multi-year cohort study will assess the real-world safety and effectiveness of 1L treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC patient subgroups defined by age, sex, race, and ethnicity. Patients will be retrospectively identified from at least two US electronic health record (EHR)-based databases.

Eligibility:
- EligibilityCriteria: Key Inclusion Criteria:  1. Advanced non-small cell lung cancer (aNSCLC) (defined as stage IIIB/C or stage IV) treated with cemiplimab in combination with platinum-doublet chemotherapy in the 1L setting from Nov 2022 to Jun 2026 as described in the protocol  Key Exclusion Criteria:  1. Patients who have EGFR, ALK or ROS1 variants  Note: Other protocol-defined Inclusion/ Exclusion Criteria apply - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with advanced disease, defined as stage IIIB, IIIC, or IV disease, with evidence of administration of 1L cemiplimab in combination with platinum-doublet chemotherapy between 08 Nov 2022 and 30 Jun 2026 and without EGFR, ALK, and ROS1 genomic variants. - SamplingMethod: Non-Probability Sample
SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary
Status: Not yet recruiting

Participant will get oral semaglutde as prescribed by the study doctor. The study will last for about 26 ± 4 weeks (5 to 7 months). Participant will be asked to complete a questionnaire about how they take oral semaglutide tablets during normal scheduled visit with doctor. Participant will also be asked questions about health and their diabetes treatment and lab tests as part of normal doctor's appointment.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/LAR and the treating physician based on local label before and independently from the decision to include the patient in this study. Male or female, adults above or equal to 18 years of age at the time of signing informed consent. Diagnosed with type 2 diabetes mellitus. Patient on metformin (Met) with or without modern oral antidiabetic (MOAD, that is Dipeptidyl Peptidase-4 Inhibitor [DPP4i] or/and Sodium-glucose cotransporter-2 Inhibitor [SGLT2i]) with or without insulin therapy. Available HbA1c value > 7.0% within 90 days prior to the 'Informed Consent and Treatment Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Informed Consent and Treatment Initiation visit' (V1) if in line with local clinical practice.  Exclusion Criteria:  Previous participation in this study (defined as having given informed consent in this study earlier). Treatment with any investigational drug within 30 days prior to enrolment into the study. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. Glucagon like peptide -1 receptor agonist (GLP1-RA) treatment within 90 days prior to the Treatment Initiation visit (V1). Patients diagnosed with type 1 diabetes mellitus. Female who is known to be pregnant, undergoing fertility treatment, breastfeeding or intends to become pregnant during the study duration. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Adult participant diagnosed with T2D and without any prior or current use of oral semaglutide. - SamplingMethod: Non-Probability Sample
Testing Two Interventions to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV
Status: Not yet recruiting

Engagement in HIV medical care and adherence to HIV medications are both essential in improving health outcomes among people living with HIV (PLH), but PLH living in rural areas-who suffer higher mortality rates than their urban counterparts-can confront multiple barriers to care engagement and adherence, especially as they face the logistical, medical, and social challenges associated with aging. This project will test the efficacy of two interventions to determine their impact on HIV health outcomes and quality of life among rural, older PLH living in the Southern U.S. The two interventions, adapted from evidence-based interventions and delivered remotely, are: (1) supportive-expressive peer social support groups and (2) strengths-based case management. We hypothesize that both interventions will increase viral suppression, antiretroviral therapy adherence, and health-related quality of life and decrease depressive symptoms. Results from this study will provide us with tools to improve health outcomes for rural older people living with HIV.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Aged 50 years or greater Living in a county with a score of .4 or higher on the index of relative rurality (IRR) Living in Alabama, Arkansas, Delaware, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, Missouri, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, or West Virginia Living with HIV Has a telephone at home Able to provide informed consent  Exclusion Criteria:  Not meeting eligibility criteria described above - HealthyVolunteers: No - Gender: All - MinimumAge: 50 Years - StdAgeList: Adult, Older Adult